Medicare formulary coverage for top-selling biologics

Nature Biotechnology

Volumn 27, Issue 12, 2009, Pages 1082-1084

  Liang, Su Ying ^a   Haas, Jennifer S ^b   Phillips, Kathryn A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BETA1A INTERFERON; BEVACIZUMAB; ETANERCEPT; INFLIXIMAB; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INTERFERON BETA SERINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TRASTUZUMAB;

ANEMIA; BIOLOGY; CLINICAL DECISION MAKING; COST; DIABETES MELLITUS; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HEPATITIS B; HEPATITIS C; LETTER; MEDICARE; MULTIPLE SCLEROSIS; NEOPLASM; NEUTROPENIA; PHARMACY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

BIOLOGICAL PRODUCTS; COST SHARING; MEDICARE PART D; PHARMACOPOEIAS AS TOPIC; UNITED STATES;

EID: 71849090160     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1209-1082     Document Type: Letter

References (12)

1. Adams, K.T. Biotechnol. Healthcare. 3, 28-35 (2006).
2. Mullins, C.D., Lavallee, D.C., Pradel, F.G., DeVries, A.R. & Caputo, N. Health Aff. (Millwood) 25, 1332-1339 (2006).
3. Robinson, J.C. Health Aff. (Millwood) 25, 1205-1217 (2006)
4. Tseng, C.W., Mangione, C.M., Brook, R.H., Keeler, E. & Dudley, R.A. J. Am. Med. Assoc. 297, 2596-2602 (2007).
5. Bowman, J., Rousseau, A., Silk, D. & Harrison, C. Health Aff. (Millwood) 25, 1240-1248 (2006).
6. Comer, B. IMS: Global biotech sales up 12.5% in 2007. (2008) http://www.mmm-online.com/IMS-Global-biotech-sales-up-125-in-2007/article/ 111366/.
7. Stern, D. & Reissman, D. J. Manag. Care Pharm. 12, 736-744 (2006).
8. Hargrave, E., Hoadley, J. & Thompson, J. Coverage and Pricing of Drugs That Can Be Covered Under Part B and Part D (MedPAC, Washington, DC, 2007).
9. Huskamp, H.A., Stevenson, D.G., Donohue, J.M., Newhouse, J.P. & Keating, N.L. Psychiatr. Serv. 58, 308-310 (2007).
10. Hargrave, E., Hoadley, J. & Merrell, K. Drugs on Specialty Tiers in Part D (MedPAC, Washington, DC, 2009).
11. Hoadley, J., Hargrave, E., Cubanski, J. & Neuman, T. Medicare Part D Data Spotlight: Specialty Tiers (Kaiser Family Foundation, Menlo Park, California, USA, 2009).
12. Walsh, B. The Tier 4 Phenomenon: Shifting the High Cost of Drugs to Consumers (AARP, Washington, DC, 2009)